Aclaris Therapeutics, Inc. (NASDAQ:ACRS) CEO Neal Walker Sells 25,000 Shares

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) CEO Neal Walker sold 25,000 shares of the firm’s stock in a transaction dated Thursday, April 21st. The shares were sold at an average price of $15.24, for a total value of $381,000.00. Following the sale, the chief executive officer now owns 1,290,763 shares in the company, valued at approximately $19,671,228.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Neal Walker also recently made the following trade(s):

• On Monday, April 25th, Neal Walker sold 20,000 shares of Aclaris Therapeutics stock. The shares were sold at an average price of $15.18, for a total value of $303,600.00.
• On Friday, March 11th, Neal Walker sold 56,303 shares of Aclaris Therapeutics stock. The shares were sold at an average price of $15.91, for a total value of $895,780.73.

Shares of NASDAQ ACRS traded up $0.18 during trading hours on Monday, hitting $15.28. The company’s stock had a trading volume of 262,449 shares, compared to its average volume of 511,608. Aclaris Therapeutics, Inc. has a 12 month low of $9.26 and a 12 month high of $26.50. The business has a 50-day simple moving average of $15.76 and a 200-day simple moving average of $14.48.

Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) last posted its quarterly earnings data on Thursday, February 24th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.01). The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.80 million. Aclaris Therapeutics had a negative net margin of 1,343.96% and a negative return on equity of 47.82%. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. As a group, equities research analysts anticipate that Aclaris Therapeutics, Inc. will post -1.84 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP boosted its position in shares of Aclaris Therapeutics by 15.4% in the 3rd quarter. Wellington Management Group LLP now owns 5,420,453 shares of the biotechnology company’s stock worth $97,568,000 after purchasing an additional 722,704 shares in the last quarter. BlackRock Inc. raised its holdings in Aclaris Therapeutics by 7.7% in the 4th quarter. BlackRock Inc. now owns 4,078,875 shares of the biotechnology company’s stock worth $59,307,000 after acquiring an additional 290,458 shares during the last quarter. Rock Springs Capital Management LP raised its holdings in Aclaris Therapeutics by 1.1% in the 3rd quarter. Rock Springs Capital Management LP now owns 3,803,232 shares of the biotechnology company’s stock worth $68,458,000 after acquiring an additional 40,920 shares during the last quarter. Commodore Capital LP raised its holdings in Aclaris Therapeutics by 22.0% in the 4th quarter. Commodore Capital LP now owns 2,672,346 shares of the biotechnology company’s stock worth $38,856,000 after acquiring an additional 482,055 shares during the last quarter. Finally, BVF Inc. IL raised its holdings in Aclaris Therapeutics by 37.3% in the 3rd quarter. BVF Inc. IL now owns 1,373,044 shares of the biotechnology company’s stock worth $24,715,000 after acquiring an additional 373,044 shares during the last quarter. 98.62% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have weighed in on the company. StockNews.com initiated coverage on Aclaris Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Zacks Investment Research downgraded Aclaris Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Aclaris Therapeutics in a report on Friday, February 25th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Aclaris Therapeutics has an average rating of “Buy” and an average price target of $30.50.

Aclaris Therapeutics Company Profile (Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Read More